Pfizer, FDA and drug chief
Megyn Kelly, Pfizer and COVID
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
Shares of Pfizer Inc. PFE slid 1.20% to $26.42 Wednesday, on what proved to be an all-around mixed trading session for the ...
Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam Feuerstein writes.
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback